Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment

• Main Authors: Chi‐Chung Li (Author), Tiffini Voss (Author), Ken Kowalski (Author), Bei Yang (Author), Huub Jan Kleijn (Author), Christopher J. Jones (Author), Rolien Bosch (Author), David Michelson (Author), Matthew DeAngelis (Author), Yang Xu (Author), Iris Xie (Author), Prajakti A. Kothare (Author)
• Format: Book
• Published: Wiley, 2020-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ubrogepant (MK‐1602) is a novel, oral, calcitonin gene‐related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure‐response (E‐R) modeling and simulations, which were used to inform the pha...